跳至主要内容
临床试验/TCTR20210729003
TCTR20210729003已完成2 期

A randomized, double-blind, split-face study of topical silymarin versus 2% hydroquinone cream in melasma

/A0 个研究点目标入组 23 人开始时间: 2021年7月29日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
23

研究概览

简要总结

After treatment, both sides showed significant improvement of RLI. Mean improvement rates of RLI were 14.56% (SD 43.09) and 12.82 % (SD 38.19) for silymarin and hydroquinone respectively. Modified MASI score decreased after both treatments but was only significant on the hydroquinone side after the first month of treatment (% reduction of modified MASI 17.98%, P 0.019). However, there were no statistically significant differences in the RL*I and modified MASI between the two treatments.

研究设计

研究类型
Interventional

入排标准

年龄范围
N/A (No limit) 至 N/A (No limit)(—)
性别
Female

入选标准

  • 25 female patients with epidermal or mixed-type melasma on both cheeks

排除标准

  • 1.Patients with pregnancy and lactation
  • 2. Received hormonal therapy or contraceptive pills within 1 year
  • 3. Received any topical treatment within 1 month
  • 4. Received laser treatment within 3 months
  • 5. Having other facial dermatologic conditions or present of any life-threatening underlying diseases

研究者

发起方
/A

相似试验